Biotechnology
Technology
Health

United Therapeutics

$118.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (0.08%) Today
+$0.09 (0.08%) Today

Why Robinhood?

You can buy or sell UTHR and other stocks, options, ETFs, and crypto commission-free!

About

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. Read More The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Employees
860
Headquarters
Silver Spring, Maryland
Founded
1996
Market Cap
5.18B
Price-Earnings Ratio
8.84
Dividend Yield
0.00
Average Volume
362.32K
High Today
$120.22
Low Today
$118.68
Open Price
$119.30
Volume
34.62K
52 Week High
$130.00
52 Week Low
$100.06

Collections

Biotechnology
Technology
Health
Pharmaceutical
Therapy
Research And Development
Silver
Metals

News

TradingNewsNowMar 14

Valuation Now: United Therapeutics Corporation (NASDAQ: UTHR)

United Therapeutics Corporation trades as part of the biotechnology industry and is part of the healthcare sector. The company CEO is Martine A. Rothblatt. United Therapeutics Corp is engaged in the healthcare sector. Its core offering includes pharmaceutical products to address unmet medical needs of patients. Previous Intraday Trading Performance: The UTHR stock showed a previous change of 3.77% with an open at 111.77 and a close of 115.56. It reached an intraday high of 118.09 and a low of 111.17. See...

8
Seeking AlphaMar 13

United Therapeutics Looks To Develop Inhaled Adcirca - A Deeper Look

When United Therapeutics (NASDAQ:UTHR) signed a deal with MannKind (MNKD) for a dry powder inhaled form of Treprostinil, the company also contracted an undisclosed compound within the PAH space.

331
PR NewswireMar 12

United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 29th Annual Healthcare Conference in New York City.

3

Earnings

$2.55
$3.26
$3.98
$4.69
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.